Clinical Trial Update: A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous tocilizumab for moderate to severe COVID-19 pneumonia has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: COVID-19 Pneumonia | Phase 2 | Status: COMPLETED | Results posted: 2021-08-30